Form 4: Vanda Pharma SVP Sells Shares for Tax Obligations

Vanda Pharmaceuticals' SVP of Business Development, Gunther Birznieks, sold 42,431 shares of common stock to cover tax obligations related to vested restricted stock units.

Summary

• Gunther Birznieks, SVP of Business Development at Vanda Pharmaceuticals Inc. (VNDA), reported a sale of common stock.
• A total of 42,431 shares were sold on March 2, 2026.
• The shares were sold at a weighted average price of $8.2659, with individual transactions ranging from $8.085 to $8.81.
• The sale was conducted to satisfy tax obligations arising from the vesting and settlement of Restricted Stock Units (RSUs).
• This transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned sale.
• Following this transaction, Mr. Birznieks beneficially owns 494,197 shares of Vanda Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine transaction to cover tax liabilities associated with vested equity compensation, not an indication of a change in sentiment or company fundamentals.

Industry Context

StockSavvy.ai notes that insider sales to cover tax obligations upon RSU vesting are a common and routine occurrence in the biotechnology and pharmaceutical industry, reflecting standard equity compensation practices rather than a change in management's outlook on the company's prospects.

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine, pre-planned transaction for tax purposes and does not reflect a change in company fundamentals or management's long-term view.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned sale of shares by an executive to cover tax obligations related to vested restricted stock units. Such transactions are common and do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this event does not provide new information to alter an existing investment thesis.

Keywords

Vanda Pharmaceuticals, VNDA, Insider Sale, Form 4, Restricted Stock Units, RSU, Tax Obligations, Gunther Birznieks, SVP Business Development, Equity Compensation